194 related articles for article (PubMed ID: 27770145)
1. Phase I/II trials of
Denis-Bacelar AM; Chittenden SJ; Dearnaley DP; Divoli A; O'Sullivan JM; McCready VR; Johnson B; Du Y; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):620-629. PubMed ID: 27770145
[TBL] [Abstract][Full Text] [Related]
2. Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Denis-Bacelar AM; Chittenden SJ; McCready VR; Divoli A; Dearnaley DP; O'Sullivan JM; Johnson B; Flux GD
Br J Radiol; 2018 Apr; 91(1084):20170795. PubMed ID: 29293372
[TBL] [Abstract][Full Text] [Related]
3. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
4. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
5. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
6. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
8. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
9. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
10. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
van Dodewaard-de Jong JM; de Klerk JMH; Bloemendal HJ; Oprea-Lager DE; Hoekstra OS; van den Berg HP; Los M; Beeker A; Jonker MA; O'Sullivan JM; Verheul HMW; van den Eertwegh AJM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1319-1327. PubMed ID: 28421240
[TBL] [Abstract][Full Text] [Related]
11. The potential of
Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
[TBL] [Abstract][Full Text] [Related]
12. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
[TBL] [Abstract][Full Text] [Related]
13. A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases.
Denis-Bacelar AM; Chittenden SJ; Murray I; Divoli A; Ralph McCready V; Dearnaley DP; O'Sullivan JM; Johnson B; Flux GD
Phys Med Biol; 2017 Apr; 62(7):2859-2870. PubMed ID: 28291739
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
15. Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Barna S; Haug AR; Hartenbach M; Rasul S; Grubmüller B; Kramer G; Blaickner M
Clin Nucl Med; 2020 Sep; 45(9):661-667. PubMed ID: 32604113
[TBL] [Abstract][Full Text] [Related]
16. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
Israel O; Keidar Z; Rubinov R; Iosilevski G; Frenkel A; Kuten A; Betman L; Kolodny GM; Yarnitsky D; Front D
J Clin Oncol; 2000 Jul; 18(14):2747-54. PubMed ID: 10894875
[TBL] [Abstract][Full Text] [Related]
17. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
van Dodewaard-de Jong JM; de Klerk JM; Bloemendal HJ; van Bezooijen BP; de Haas MJ; Wilson RH; O'Sullivan JM
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1990-8. PubMed ID: 21792569
[TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
20. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
